GLP-1 Medication vs. Endoscopic Sleeve Gastroplasty (ESG) Compared
GLP-1 medications and endoscopic sleeve gastroplasty (ESG) produce weight loss in a similar range: about 13.6% at one year for ESG in its randomized trial, and about 15% to 21% for semaglutide and tirzepatide in theirs. The real difference is how you pay and what happens next. A GLP-1 is an ongoing monthly cost that works while you take it. ESG is a one-time procedure whose long-term results depend more on your habits and are still being studied.
Key takeaways
- In the MERIT randomized trial, ESG produced 13.6% total body weight loss at 12 months; longer-term case series report about 15% to 17.5%.
- Tirzepatide (up to 20.9%) and semaglutide (14.9%) matched or exceeded that in their pivotal trials, but most people regain weight after stopping.
- ESG gained a Category I CPT billing code on January 1, 2026, yet insurance coverage is still described as "emerging," and prices are not publicly standardized.
- The American Society for Metabolic and Bariatric Surgery recommends ESG mainly for a BMI of 30 to 40 and says it can be combined with obesity medications.
What you're actually choosing between
GLP-1 medications such as Wegovy (semaglutide), Zepbound (tirzepatide), and the newer Foundayo (orforglipron) pill are taken weekly or daily for as long as they keep working. ESG is an outpatient procedure in which a doctor uses an endoscope passed through the mouth to stitch the stomach into a smaller, sleeve-like shape. There are no incisions. The Mayo Clinic describes it as taking about 1 to 2.5 hours under general anesthesia, with most people going home the same day.
ESG sits between medication and bariatric surgery. The ASMBS says it does not consider ESG equivalent to sleeve gastrectomy or gastric bypass for weight loss or metabolic effect. That makes the GLP-1 comparison the more relevant one for most ESG candidates.
Side-by-side comparison
| Factor | GLP-1 medication | Endoscopic sleeve gastroplasty |
|---|---|---|
| What it involves | Weekly injection or daily pill, ongoing | One-time outpatient endoscopic procedure under general anesthesia |
| Weight loss in key trials | 14.9% at 68 weeks (semaglutide, STEP 1); 20.9% at 72 weeks (tirzepatide 15 mg, SURMOUNT-1) | 13.6% at 12 months (MERIT randomized trial); 15% to 17.5% in longer case series |
| Durability | Depends on staying on the drug; 14% regain within a year of switching to placebo (SURMOUNT-4) | Regain possible without lifestyle changes; MERIT's randomized comparison ran 52 weeks |
| Who it's for | Adults with obesity, or overweight with a weight-related condition (FDA labels) | ASMBS recommends mainly for BMI 30 to 40 |
| Cost | About $149 to $449/month self-pay; $50/month for eligible Medicare beneficiaries | Not publicly standardized; coverage "emerging"; often self-pay |
| Downtime | None, but GI side effects during dose increases | Same-day discharge in most cases; liquid diet for at least 2 weeks |
| Main risks | Nausea, vomiting, diarrhea; pancreatitis and gallbladder warnings; thyroid tumor boxed warning | Pain and nausea for several days; rare bleeding, leak, infection |
| Can it be undone? | Stop the drug | Described as reversible for most patients; can be converted to surgery, though that may be more complex |
Source: ASMBS ESG FAQ, Mayo Clinic, Johns Hopkins Medicine, ACC (STEP 1), ACC (SURMOUNT-1), JAMA (SURMOUNT-4), manufacturer pricing.
Results: closer than most people expect
ESG's best evidence is the MERIT randomized trial, which enrolled 209 adults with a BMI of 30 to 40. At 52 weeks, those who had ESG lost 13.6% of total body weight on average, versus 0.8% in the lifestyle-only control group, and ESG-related serious adverse events occurred in 2% of procedures (The Lancet, 2022). Longer observational series report 15% to 17.5%. Johns Hopkins tells patients to expect to lose about 12% to 20% of their body weight within a year.
The GLP-1 trial numbers are in the same range or higher. Semaglutide 2.4 mg produced 14.9% weight loss at 68 weeks versus 2.4% on placebo in STEP 1 (ACC). Tirzepatide produced 15% to 20.9% depending on dose at 72 weeks in SURMOUNT-1 (ACC). The ASMBS itself notes that ESG and obesity medications "can produce similar weight-loss ranges in some populations."
Durability: the real dividing line
GLP-1 results last about as long as the prescription. In SURMOUNT-4, people who lost weight on tirzepatide and were then switched to placebo regained 14% of body weight over the following year, while those who stayed on it lost another 5.5% (JAMA, 2024).
ESG does not require ongoing medication, which is its central appeal. But durability is not guaranteed. The Mayo Clinic warns that weight regain is possible if recommended lifestyle changes are not maintained. The ASMBS says data quality and durability "remain active areas of debate." MERIT's randomized comparison lasted 52 weeks; at 104 weeks, 41 of 60 ESG patients with follow-up (68%) still had at least 25% excess weight loss (The Lancet, 2022).
Comparing medication with a procedure?
Check current GLP-1 program pricing so you can run the numbers side by side.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Cost: a one-time bill vs. a monthly one
As of October 2026, self-pay GLP-1 prices look like this:
- Wegovy: $349 a month for injections; the pill launched at $149 to $299 depending on dose (Fierce Pharma).
- Zepbound: $299 for the starting dose and as low as $449 for maintenance doses with Lilly's self-pay card, which runs through December 31, 2026 (Lilly).
- Medicare: Eligible beneficiaries pay $50 a month for Wegovy, Foundayo, or the Zepbound KwikPen through the Medicare GLP-1 Bridge.
Both companies price a "month" as a four-week supply, so a year takes about 13 fills. At those prices, a year of Wegovy injections costs about $4,537 and five years about $22,685. A year of Zepbound at the $449 maintenance price costs about $5,837, or about $29,185 over five years. Those totals assume prices stay flat, and self-pay prices have been moving: Wegovy injections dropped from $499 to $349 a month in November 2025.
ESG pricing is harder to pin down. There is no published national price, and the Mayo Clinic notes it "may not be covered by health insurance." The procedure received a Category I CPT code effective January 1, 2026, which the ASMBS says comes with "emerging coverage and benefit design." If you get an ESG quote, ask whether it includes the anesthesia, facility fee, follow-up visits, and dietitian program, then compare it with the multi-year medication totals above.
Safety and recovery
ESG: Pain and nausea can last several days but are usually managed with medicine (Mayo Clinic). Diet moves from liquids for at least two weeks to soft foods and then regular meals. Johns Hopkins calls the risk of serious complications "very small" and lists bleeding, infection, stomach tears, leaks, and blood clots in the lungs among them. ESG may not suit people with a large hiatal hernia, ulcers, or bleeding disorders. The ASMBS says published serious complication rates fall between those of GLP-1 therapy and bariatric surgery.
GLP-1s: There is no procedure, but side effects are common early on. On the Wegovy label, nausea affected 44% of users versus 16% on placebo, and vomiting 24%. Warnings include pancreatitis, gallbladder disease, and a boxed warning about thyroid C-cell tumors seen in rodents.
You may not have to choose
The ASMBS says ESG can be used with or without obesity medications and that experts expect combined approaches to become more common. Some people start with a GLP-1 and consider ESG if they plateau or cannot keep paying for the drug. Others add medication after ESG to limit regain. The ASMBS also cautions that ESG may make a later sleeve gastrectomy or bypass more complex, which matters if surgery is a likely future step.
Which fits you better
A GLP-1 may fit better if
- You want the largest average weight loss available without surgery, especially from tirzepatide.
- You have coverage or qualify for the Medicare Bridge.
- You want to avoid anesthesia and an endoscopic procedure.
- You are comfortable treating obesity as a long-term medication condition.
ESG may fit better if
- Your BMI is roughly 30 to 40 and you want to avoid lifelong medication costs.
- You could not tolerate GLP-1 side effects or cannot take them for medical reasons.
- You can commit to the diet and follow-up program that ESG results depend on.
- You can get a clear, all-inclusive price and are prepared to pay it upfront if insurance does not.
The verdict
For most people, a GLP-1 is the more practical first step. It matches or beats ESG's one-year weight loss in trials, needs no procedure, and is easier to access through insurance or Medicare. ESG is a reasonable alternative for people with a BMI of roughly 30 to 40 who cannot tolerate or sustain medication, and who will commit to the lifestyle program that keeps results in place. Its long-term durability is still debated, and costs vary by center, so get a full written quote and ask your gastroenterologist or bariatric team how ESG would affect future options.
Price out the medication route
See providers' current GLP-1 pricing to compare against any procedure quote.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
Does ESG work better than Wegovy or Zepbound?
Not on average. ESG produced 13.6% weight loss at 12 months in the MERIT randomized trial, while semaglutide produced 14.9% in STEP 1 and tirzepatide up to 20.9% in SURMOUNT-1. The ASMBS says the two can produce similar weight-loss ranges in some populations.
Is ESG covered by insurance?
Often not yet. ESG received a Category I CPT code effective January 1, 2026, but the ASMBS describes coverage as emerging, and the Mayo Clinic notes it may not be covered, so confirm with your plan.
How long do ESG results last?
Longer case series report about 15% to 17.5% weight loss, and in the MERIT trial 68% of ESG patients followed to two years kept at least 25% excess weight loss. The ASMBS says durability remains debated, and regain is possible if lifestyle changes are not maintained.
Can you take a GLP-1 after ESG?
Yes. The ASMBS says ESG can be used with or without obesity medications and expects combined approaches to become more common. Tell your care team if you are on a GLP-1 before any sedated procedure.
Who is a candidate for ESG?
The ASMBS recommends ESG mainly for adults with a BMI of 30 to 40 who have not lost enough weight with lifestyle changes and medications. It may not suit people with a large hiatal hernia, ulcers, or bleeding disorders.
Sources
- Abu Dayyeh BK et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. The Lancet 2022;400(10350):441-451
- Endoscopic Sleeve Gastroplasty (ESG) Frequently Asked Questions, ASMBS
- Endoscopic sleeve gastroplasty, Mayo Clinic
- Endoscopic sleeve gastroplasty, Johns Hopkins Medicine
- STEP 1 trial summary, American College of Cardiology
- SURMOUNT-1 trial summary, American College of Cardiology
- Continued tirzepatide for maintenance of weight reduction (SURMOUNT-4), JAMA (2024)
- Wegovy prescribing information, FDA (2025)
- Wegovy pill launches at $149 per month, Fierce Pharma
- Zepbound coverage and savings, Eli Lilly
- Medicare GLP-1 Bridge: GLP-1 drugs for $50 a month, Medicare.gov
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.